Technology
Health
Pharmaceutical

Tonix Pharmaceuticals

$2.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.13 (6.84%) Today
-$0.03 (-1.48%) After Hours

Why Robinhood?

You can buy or sell TNXP and other stocks, options, ETFs, and crypto commission-free!

About

Tonix Pharmaceuticals Holding Corp. Common Stock, also called Tonix Pharmaceuticals, is a clinical-stage biopharmaceutical company, which engages in discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Read More It focuses on delivering a safe and effective long-term treatment for posttraumatic stress disorder. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Employees
12
Headquarters
New York, New York
Founded
2007
Market Cap
12.36M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
662.41K
High Today
$2.04
Low Today
$1.88
Open Price
$1.95
Volume
283.52K
52 Week High
$51.10
52 Week Low
$1.55

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2013 IPO
US
North America

News

Seeking AlphaMay 23

Tonix up 9% premarket on new pipeline candidate

Tonix Pharmaceuticals (NASDAQ:TNXP) has in-licensed a Phase 2 asset, TNX-1300 (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution) for the treatment of cocaine intoxication.

407
Seeking AlphaMay 22

Tonix perks up 17% as capital raise looms

Nano cap Tonix Pharmaceuticals (TNXP +17% ) is up on below-average volume. Shares have jumped 30% since Monday but remain mired in a pronounced downtrend that began in July of last year after lead drug Tonmya (cyclobenzaprine HCl sublingual tablets) failed a late-stage study in posttraumatic stress disorder. The stock has lost over 90% of its value since then. No particular news accounts for the recent action, although the company will soon need to execute a capital raise. In its most recent 10-Q, it state...

268
NasdaqMay 8

Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, "We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company. We have benefitted from ...

287

Earnings

-$6.10
-$4.26
-$2.41
-$0.57
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.08 per share
Actual
-$1.29 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.